Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 2
2004 1
2006 2
2008 3
2009 1
2011 4
2013 1
2014 1
2015 2
2016 12
2017 5
2018 4
2019 2
2021 2
2022 8
Text availability
Article attribute
Article type
Publication date

Search Results

45 results
Results by year
Filters applied: . Clear all
Page 1
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Zeissig S, Rosati E, Dowds CM, Aden K, Bethge J, Schulte B, Pan WH, Mishra N, Zuhayra M, Marx M, Paulsen M, Strigli A, Conrad C, Schuldt D, Sinha A, Ebsen H, Kornell SC, Nikolaus S, Arlt A, Kabelitz D, Ellrichmann M, Lützen U, Rosenstiel PC, Franke A, Schreiber S. Zeissig S, et al. Among authors: lutzen u. Gut. 2019 Jan;68(1):25-39. doi: 10.1136/gutjnl-2018-316023. Epub 2018 May 5. Gut. 2019. PMID: 29730603
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ. Rahbar K, et al. Among authors: lutzen u. J Nucl Med. 2017 Jan;58(1):85-90. doi: 10.2967/jnumed.116.183194. Epub 2016 Oct 20. J Nucl Med. 2017. PMID: 27765862 Free article.
The future of radiosynoviorthesis - bright or bleak?
Freudenberg LS, Sewerin P, Ohlerth SM, Pomykala KL, Freudenberg S, Rischpler C, Lützen U. Freudenberg LS, et al. Among authors: lutzen u. Q J Nucl Med Mol Imaging. 2022 Jun 16. doi: 10.23736/S1824-4785.22.03475-6. Online ahead of print. Q J Nucl Med Mol Imaging. 2022. PMID: 35708602
45 results